Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter
Acorda Therapeutics saw its shares get crushed early on Tuesday after the firm received a Refusal to File letter from the FDA in regards to its New Drug Application for Inbrija.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 160Gilead Moves to Acquire Kite Pharma
Gilead Sciences shares have been in a holding pattern for a while. Analysts have said that the firm needs to make a move to shake this situation, otherwise this could turn into something worse.
Short Sellers Can’t Make Up Their Minds on Major Biotechs
The August 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Short Sellers Run for Cover From Major Pharma
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
How the Ultragenyx Hype Went From a Very Promising to a 52-Week Low
Ultragenyx Pharmaceutical just hit a 52-week low and analysts have slashed and burned their price target expectations. This is after a late-stage trial did not live up to expectations.
Ultragenyx Stumbles Over Late-Stage Trial
Ultragenyx Pharmaceutical shares took a turn for the worse on Wednesday after a report that results from its late-stage trial did not live up to expectations.
Intra-Cellular Soars on Critical FDA Update
Intra-Cellular Therapies saw its shares make an incredible gain early on Wednesday after the FDA gave a positive regulatory update on the firm’s schizophrenia program.
Krystal Biotech Files for IPO
Gene therapy company Krystal Biotech has filed with the SEC regarding its initial public offering.
Analysts Say Sienna Biopharmaceuticals Stock Could Run 50% to 100%
The quiet period for Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) is over after its initial public offering. The Westlake Village, California-based company recently sold just 4,983,333 shares of common stock at $15.00 per share in…
Coherus Bio Jumps on Private Placement
Coherus Biosciences, Inc. (NASDAQ: CHRS) watched its shares jump on Monday after the company announced that it plans to raise up to $150 million in a two tranche private placement. A Singapore investment firm,…
Ironwood Pharma Muted Despite FDA Approval
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment duzallo. The firm expects duzallo to…
Syros Pharma Wins Orphan Designation From FDA
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) saw its shares make a handy gain early on Monday after the firm announced a critical update that it received from the U.S. Food and Drug Administration. Specifically, the…
Valeant Pharmaceuticals Gets Boost From FDA Update
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) saw its shares make a handy gain on Thursday after the company provided an update from the U.S. Food and Drug Administration (FDA). Specifically, the agency confirmed that…
FibroGen Prices Follow-On Offering
Shares of FibroGen saw a handy gain on Wednesday after the biopharmaceutical company announced the pricing of its underwritten follow-on offering.
Government Share of ACA Premium Hikes Adds $194 Billion to Federal Deficit
The Congressional Budget Office has estimated that maintaining cost-sharing reduction payments to health insurers will add $194 billion to the federal deficit between over 10 years.